Drug intelligence / Profile preview

Nidadd

Development stage: Phase 3
Lead developer: Genovate Biotechnology
Modality: Small Molecules
Administration: Oral

Overview

Nidadd is an extended-release formulation of niacin, also known as vitamin B3, developed by Genovate Biotechnology Co., Ltd. It is being investigated for the management of hyperlipidemia, a condition characterized by high levels of cholesterol and triglycerides in the blood. Niacin works through multiple mechanisms to improve lipid profiles, including reducing the synthesis and increasing the degradation of 'bad' cholesterol (LDL and VLDL) and raising 'good' cholesterol (HDL).

Other names: extended-release niacin

Targets

HCAR2 (Hydroxycarboxylic acid receptor 2)DGAT2 (Hepatic diacylglycerol acyltransferase 2)

Beyond the preview

Go deeper on Nidadd.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nidadd.

Explore the full profile